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Objectives: DNA fragmentation factors 40 and 45 (DFF40 and DFF45) are responsible for 
final DNA-laddering during apoptosis, whereas Bcl-2 (B-cell lymphoma 2) is an apoptosis 
inhibitor. Our aim was to investigate the expression of DFF40, DFF45, and Bcl-2 in uterine 
leiomyosarcomas (uLMS), leiomyomas (uLM), and the normal myometrium. Furthermore, the 
correlation between DFF40, DFF45, and Bcl-2 expression and clinicopathological parameters 
in leiomyosarcomas was assessed. Their prognostic value in disease-free survival (DFS) and 
overall survival (OS) was also calculated.
Materials and methods: This study included 53 cases of uLMS from patients matched for age 
and menopausal status with 53 cases of uLM and 53 controls of normal myometrium (uM). Case 
samples of uterine myometrium from leiomyosarcomas (uLMS-M) and leiomyomas (uLM-M) were 
also studied. Immunohistochemical scoring was undertaken for DFF40, DFF45, and Bcl-2.
Results: DFF40, DFF45, and Bcl-2 were significantly underexpressed in uLMS compared with 
uLMS-M and uM. In uLMS samples, no correlation between the analyzed proteins was observed. 
Negative DFF40 and Bcl-2, but not DFF45, staining was a predictor of poorer DFS and OS in 
women with uLMS. uLM showed DFF40 and Bcl-2 overexpression compared with uM and 
uLM-M, with a significant positive correlation between DFF40 and DFF45. No differences in 
DFF40, DFF45, and Bcl-2 expression were observed between the uLMS-M, uLM-M, and uM 
samples, with a significant positive correlation between DFF40 and DFF45 expression.
Conclusion: DFF40, DFF45, and Bcl-2 are significantly underexpressed in uLMS, but only a 
lack of DFF40 and Bcl-2 negatively influences DFS and OS. Disruption of DFF40 and DFF45 
expression was observed in uLMS, but not in uLM or control and case myometrium; this may 
play a role in tumor pathogenesis.
Keywords: B-cell lymphoma 2, disease-free survival, DNA fragmentation factor 40, DNA 
fragmentation factor 45, uterine, immunohistochemistry, leiomyosarcoma, uterine leiomyoma, 
overall survival
Introduction
Uterine leiomyosarcomas (uLMS) are rare malignant tumors arising within the 
myometrium, and account for 1%–2% of all uterine corpus malignancies; however, 
cervical localization of uLMS has also been reported.1–3 These represent the most 
common subtype of uterine sarcoma, with a stable incidence over the past three 
decades.4,5 Prior pelvic irradiation, use of tamoxifen, and African-American ethnicity 
have been reported to increase the risk of uLMS.6–8
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In contrast to uLMS, uterine leiomyoma (uLM) is the 
most common gynecological pathology, affecting up to 80% 
of the female population.9 Although possible progression 
from uLM to uLMS has been postulated, the risk of malignant 
transformation of uLM is low, accounting for less than 1% of 
all cases. Recent clonality studies have confirmed that most 
uLMS arise de novo.10–12 Proven clinical and pathological 
prognostic factors for uLMS are age, stage, grade (G), and 
mitotic index (MI), whereas prognostic biomarkers have not 
been consistently shown.5,13–15
Changes in the expression of Bcl-2, an anti-apoptotic 
protein, have been reported in several malignancies, includ-
ing breast and cervical cancers, ovarian malignant epithe-
lial tumors, endometrial carcinomas, as well as in uLMS; 
these tumors also show downregulated p53 and caspase-9 
expression.16–22 Caspases (cysteine-aspartic proteases) can 
be activated via the mitochondrial or cytoplasmic pathways 
and as a result of cellular oxidative stress; their activation 
leads to activation of DNA fragmentation factors (DFF) in 
the nucleus, which are directly responsible for DNA frag-
mentation and cellular apoptosis.23 The DFF complex exists 
as a dimer composed of DFF40 (caspase-activated DNase; 
CAD) and DFF45 (inhibitor of caspase-activated DNase; 
ICAD).24 After DFF45 cleavage by caspase-3, the active form 
of DFF40 is released, which promotes DNA fragmentation 
(DNA laddering).24 However, DFF45 is not a simple inhibitor 
of DFF40, as its presence is essential for the proper folding 
of DFF40 into the active protein.24
The association between expression of these proteins 
and prognosis in various tumors has also been investigated. 
According to Hwang et al, Bcl-2 expression was a strong 
favorable prognostic factor in the HR(+)/HER2(−) subtype of 
breast cancer and a marginally significant favorable prognos-
ticator in the HR(+)/HER2(+), but had no prognostic impact 
on other subtypes.29 In contrast, no significant correlation was 
seen between Bcl-2 expression and clinicopathological param-
eters of colorectal cancer.26 Lack of Bcl-2 expression was also 
shown to be an independent predictor of poor prognosis in 
endometrial cancers.30,31 In human uterine smooth muscle 
tumors, a significantly lower Bcl-2 expression was observed 
in leiomyosarcomas than in leiomyomas, and positive Bcl-2 
expression has been proven to be an independent predictor 
of favorable prognosis in patients with leiomyosarcomas.32 
Decreased DFF45 expression has been observed in renal, 
colorectal, and esophageal cancers, and it has been postu-
lated that its downregulation (although unexpected at first 
glance) may play a role in tumor escape from apoptosis and 
may promote tumor progression and metastasis.33–35
The aim of this retrospective case–control study was 
to evaluate the expression of DFF40, DFF45, and Bcl-2 as 
potential prognostic biomarkers in uLMS.
Materials and methods
case selection
In this retrospective study, 57 patients with primary uLMS 
were identified between 2000 and 2015. Inclusion criteria 
were patients older than 18 years with pathologically con-
firmed primary solitary uLMS; their histological diagnosis 
was reevaluated and confirmed. Patients who had additional 
malignancies, were smokers, had received hormonal treat-
ment (including hormonal contraception) over the past 
5 years, had been diagnosed with smooth muscle tumors of 
uncertain malignant potential or cellular and bizarre leio-
myoma, or had missing clinical data were excluded. Finally, 
53 uLMS cases were compared with 53 age-matched cases of 
solitary uLM and 53 matched cases of normal human uterine 
myometrium (uM). In cases of uLMS and uLM, additional 
myometrial samples were obtained at least 20 mm away from 
the primary tumor.
Every uLMS was staged according to the International 
Federation of Gynecology and Obstetrics (FIGO) 2009 
classification, and the tumor grade and MI were calculated 
for all uLMS as the number of mitoses in 10 consecutive 
high-power fields (hpf) at 400× magnification that were 
also analyzed. Patients with stage I and II uLMS underwent 
total hysterectomy with bilateral salpingo-oophorectomy 
(BSO) and pelvic lymph node biopsy, whereas those with 
stages III and IV disease underwent complete cytoreductive 
surgery, which allowed us to obtain archive specimens of 
uLMS tissue and concomitant uterine myometrium. Women 
with uLM underwent supracervical hysterectomy with bilat-
eral salpingectomy or salpingo-oophorectomy, if clinically 
justified, to obtain uLM and related uterine myometrium 
specimens. Additionally, uM was obtained from patients 
who suffered from recurrent or persistent cervical dysplasia 
with no otherwise diagnosed myometrial pathology, and 
total hysterectomy was undertaken as the final treatment. All 
specimens were collected premenstrually, in the first phase 
of the menstrual cycle, which was confirmed using histo-
pathological examination of the concomitant endometrium. 
Clinical data were retrieved from medical files.
immunohistochemistry
Detailed immunohistochemistry protocols have been pre-
sented in earlier reports.36,37 In brief, 3-µm sections of selected 
tissues were deparaffinized and rehydrated, then incubated 
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4581
Predictive value of DFF40/DFF45 and Bcl-2 in uterine leiomyoscarcomas
in a target retrieval solution (Dako, Carpinteria, CA, USA) for 
15 min at 98°C. They were then incubated with 3% hydrogen 
peroxide in methanol for 10 min, and washed with TRIS-
buffered saline (pH 7.5) for a further 10 min. The sections 
were incubated with diluted normal serum as a blocking 
solution for 30 min. A standard immunohistochemical 
technique was performed using rabbit polyclonal antibodies 
to DFF40 (Abcam, Cambridge, UK) (1:100 dilution) and 
DFF45 (Abcam, Cambridge, UK) (1:50 dilution), and a mono-
clonal mouse anti-human antibody to Bcl-2 (1:200 dilution; 
Leica Microsystems GmbH, Leica Biosystems, Nussloch, 
Germany). Colon carcinoma (for Bcl-2), breast carcinoma (for 
DFF45), and ovary tissue (for DFF40) were used as positive 
controls. For the negative control, the same specimens and 
methods were used, but the primary antibodies were omitted.
immunohistochemical scoring
DFF45, DFF40, and Bcl-2 staining was blindly and inde-
pendently evaluated by two board-certified pathologists 
in 5 hpf of maximal staining intensity. The Remmele and 
Stanger immunoreactive score was used, and each sample 
was scored based on the intensity of staining (0, no staining; 
1, weak staining; 2, moderate staining; and 3, strong stain-
ing) and the number of stained cells (0, expression in up to 
10% of the cells; 1+, expression in 10%–50% of the cells; 
2+, expression in 51%–80% of the cells; and 3+, expression 
in more than 80% of the cells).38 The final immunoreactivity 
score was determined by multiplying the intensity scores 
by the extent of the positivity scores of the stained cells. 
A discrepancy between the observations by the two patholo-
gists occurred in 18 (2.74%) cases, and the samples were 
verified again 2 weeks after the primary evaluation to prevent 
recall bias. In all cases, a consensus was achieved and no 
samples required exclusion from the analysis.
statistical analyses
Clinical features presented non-normal distributions (con-
firmed using the Kolmogorov–Smirnov test) and are presented 
as the medians and interquartile range (IQR) or rough number 
and percentage (%). They were compared using the Mann–
Whitney U test, or the Kruskal–Wallis analysis of variance 
test, depending on the number of groups. Post hoc tests were 
used where appropriate. Immunohistochemical scoring of 
tissue specimens was evaluated using the chi-square test.39 
Data from the immunohistochemistry results are presented as 
numbers and percentage of immunoscoring. Spearman’s rank 
test was used to determine the correlation of immunoscoring 
and pathological features. A Kaplan–Meier survival curve 
was prepared according to the DFF40, DFF45, and Bcl-2 
expression status. Cox’s proportional hazard model was used 
to identify survival predictors, and the Cox–Mantel test was 
used to compare overall survival (OS) (defined as the period 
between initial surgery and the time of death) and disease-free 
survival (DFS) (defined as the period between initial surgery 
and the time of recurrence). To evaluate the intra-rater agree-
ment of the immunohis tochemistry results, the intraclass 
correlation coefficient (ICC) for a single histopathological 
evaluation with a 95% confidence interval (CI) was calcu-
lated. To randomize patients who underwent evaluation for 
intra-rater agreement, we used the Research Randomizer 
(www.randomizer.org), and 55 (20.91%) samples were 
chosen and reevaluated separately for DFF40, DFF45, and 
Bcl-2 after a 2-week interval from the primary evaluation to 
prevent recall bias. The Guidelines for Reporting Reliability 
and Agreement in Studies were used to verify these results.40 
A p-value of less than 0.05 was considered significant. All 
calculations were conducted using STATISTICA version 
12.0 (StatSoft, Inc., Tulsa, OK, USA) and MedCalc Sta-
tistical Software version 17.0.4 (MedCalc Software bvba, 
Ostend, Belgium).
ethical approval and informed consent
This retrospective, case–control study was approved by 
the Jagiellonian University Review Board (decision no: 
122.6120.360) with the required informed consents from 
participants. All procedures were carried out in accordance 
with the ethical standards of the institutional and national 
research committees and in the spirit of the principles of the 
1964 Declaration of Helsinki and its later amendments.
Results
clinicopathological variables
The median age of the 53 patients with uLMS was 51 years 
(IQR 8). The number of cases with each FIGO stage was as 
follows: 27 (50.95%) with Stage I, 5 (9.43%) with Stage II, 
12 (22.64%) with Stage III, and 9 (16.98%) with Stage IV. The 
tumor grading (G) was as follows: G
1
 6 cases (11.32%); G
2
 10 
cases (18.87%), and G
3
 37 cases (69.81%), with a median MI of 
37.00 (IQR 30.00; range 12.00–123.00). The median OS was 
58.00 months (IQR 54.00; range 6–155) and the median DFS 
was 31.00 months (IQR 34.00; range 2–155). As cases were 
matched according to age and menopausal status, there were no 
differences in the last two factors. The control group showed 
a significantly higher mean age of menarche compared with 
women with uLMS (p=0.002) and uLM (p=0.012; Table 1). 
No differences in parity and menstrual cycle characteristics 
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were noticed, except for the type of menstrual bleeding 
between donors of uM, uLM, and uLMS specimens; women 
with uLMS and uLM reported statistically significantly more 
frequent abnormal vaginal spotting than controls (21/53 
[39.62%] vs 6/53 [11.32%], p0.001, and 26/53 [49.06%] vs 
6/53 [11.32%], p0.001, respectively; Table 1).
DFF40, DFF45, and Bcl-2 expression in 
uterine leiomyosarcomas
Bcl-2 showed cytoplasmic localization, while both DFF40 
and DFF45 showed a nuclear pattern of expression (Figure 1). 
Only seven (13.21%) uLMS tissues had moderate expression 
of DFF40 and three (5.66%) showed moderate expression 
Table 1 Patient characteristics for uterine leiomyosarcoma (ulMs), uterine leiomyoma (ulM), and normal myometrium cases (uM)
Uterine  
leiomyosarcomas 
(uLMS) n=53
Uterine 
leiomyomas 
(uLM) n=53
Uterine control 
myometrium  
(uM) n=53
p-value
Median age at therapy, years (iQr); min–max 51.00 (8.00);
44.00–70.00
n/a
Menopausal status, n (%)
Pre–
Post
30 (56.61%)
23 (43.39%)
n/a
FigO stage, n (%)
i
ii
iii
iV
27 (50.95%)
5 (9.43%)
12 (22.64%)
9 (16.98%)
n/a n/a n/a
grade, n (%)
1
2
3
6 (11.32%)
10 (18.87%)
37 (68.81%)
n/a n/a n/a
Median primary tumor size, cm (iQr); min–max 5.00 (7.00);
2.00–15.00
6.00 (2.00);
3.00–13.00
n/a 0.733
Mitotic index, no of mitoses per 1 high power field, n (%)
50
50
38 (71.70%)
15 (28.30%)
n/a n/a n/a
adjuvant treatment, n (%)
none
radiotherapy (rTh)
chemotherapy (chT)
combination of rTh and chT
21 (39.63%)
5 (9.43%)
22 (41.51%)
5 (9.43%)
n/a n/a n/a
Median age of first menstrual period, years (IQR); min–max 12.00 (2.00);
9.00–15.00
12.00 (2.00);
10.00–15.00
13.00 (1.00);
10.00–15.00
p=0.009*
Median age of menopause, years (iQr); min–max (n=23) 54.00 (2.00);
49.00–55.00
52.00 (4.00);
48.00–55.00
52.00 (1.00);
50.00–54.00
p=0.061
Median duration of menstrual cycle, days (iQr); min–max 28.00 (2.00);
24.00–32.00
28.00 (1.00)
25.00–34.00
28.00 (0.00)
26.00–31.00
p=0.408
Median duration of menstruation, days (iQr), min–max 4.00 (1.00);
3.00–7.00
4.00 (1.00);
3.00–7.00
4.00 (1.00);
3.00–6.00
p=0.281
Menstrual cycles, n (%)
regular
irregular
36 (67.92%)
17 (32.08%)
32 (60.38%)
21 (39.62%)
42 (79.25%)
11 (20.75%)
p=0.164
Menstrual cycles, n (%)
Painful
Painless
13 (24.53%)
40 (75.47%)
15 (28.31%)
38 (71.69%)
9 (16.98%)
44 (83.08%)
p=0.510
Type of menstrual bleeding, n (%)
scant
normal
heavy
4 (7.55%)
37 (69.81%)
12 (22.64%)
2 (3.77%)
36 (67.92%)
15 (28.31%)
4 (7.55%)
46 (86.79%)
3 (5.66%)
p=0.038*
Parity, n (%)
nullipara
Primipara
Multipara
5 (9.43%)
4 (7.55%)
44 (83.02%)
3 (5.66%)
9 (16.98%)
41 (77.36%)
2 (3.77%)
5 (9.43%)
46 (86.80%)
p=0.403
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics classification of uLMS; IQR, interquartile range.
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of Bcl-2. High expression of the studied proteins was 
absent from all uLMS samples (Table 2). DFF40 expres-
sion in uLMS was significantly lower than that in both uM 
(p0.001) and uLMS-M (p0.001). Similarly, DFF45 
expression in uLMS was significantly lower than that in 
uM (p0.001) and uLMS-M (p0.001; Table 2). Bcl-2 
expression in uLMS specimens was also significantly lower 
than that in uM (p0.001) and uLMS-M (p=0.001; Table 2). 
In uLMS specimens, no correlations between DFF40 and 
DFF45, Bcl-2 and DFF40, or Bcl-2 and DFF45 expression 
were observed. Bcl-2 showed a significant inverse moder-
ate correlation with tumor stage (R =−0.368; p=0.007) and 
MI (R =−0.301; p=0.029), but not with tumor diameter or 
grade. DFF40 but not DFF45 correlated inversely with the MI 
(R =−328; p=0.016), whereas both DFF40 and DFF45 cor-
related negatively with the stage of the disease (R =−0.300; 
p=0.029; R =−0.301; p=0.029, respectively); however, their 
expression did not correlate with tumor grade.
Women with uLMS that was negative for DFF40 and 
Bcl-2 staining showed significantly shorter OS than the OS 
of those whose specimens showed positive staining (p0.001 
and p0.001, respectively), while there was no relation-
ship between DFF45 expression and OS (Figure 2). OS in 
patients with stages III and IV disease (p0.001), a G
3
 tumor 
(p=0.016), and an MI over 50 was poorer (Figure 2). Simi-
larly, patients whose specimens tested negative for DFF40 
and Bcl-2 (but not DFF45; p=0.342) expression showed 
significantly shorter DFS (p0.001 and p0.001, respec-
tively; Figure 3). Patients with advanced stages of disease 
and higher grades and MI also had poorer DFS (p0.001, 
p=0.028, and p0.001, respectively; Figure 2).
Negative DFF40 and Bcl-2 expression, but not DFF45, 
were adverse prognostic factors for DFS and OS in women 
with uLMS. Further analysis showed that an advanced dis-
ease stage, high tumor grade, and elevated MI were associ-
ated with a reduction in OS and DFS (Table 3).
DFF40, DFF45, and Bcl-2 expression 
in ulM
uLM showed marked nuclear expression of DFF40/DFF45 
and cytoplasmic expression of Bcl-2 (Figure 2). DFF40 
expression in uLM was significantly higher than that in uM 
and uLM-M (p=0.001 and p=0.005, respectively; Table 2). 
No significant differences in DFF45 scoring between uLM 
and uM, nor between uLM and uLM-M were observed 
(Table 2). In addition, uLM showed the highest Bcl-2 
expression, as compared with uM (p0.001) and uLM-M 
(p0.001). In uLM, we found a significant positive cor-
relation between DFF40 and DFF45 expression (R =0.388; 
p=0.004) and between DFF40 and Bcl-2 expression (R =0.630; 
p0.001); however, there was no correlation between DFF45 
and Bcl-2 expression. Bcl-2 expression correlated posi-
tively and significantly with the diameter of the leiomyoma 
(R =0.435; p0.001).
DFF40, DFF45, and Bcl-2 expression in 
uterine myometrium
Myometrial samples showed a nuclear pattern of DFF40/
DFF45 and cytoplasmic of Bcl-2 staining. Only four (7.55%) 
samples of the control uM were DFF40-negative, whereas 30 
(56.60%) presented with low, 16 (30.19%) with moderate, 
and three (5.66%) with high DFF40 expression. Similarly, 
Figure 1 Weak DFF40, DFF45, and Bcl-2 expression (400×) in uterine leiomyosarcomas (red arrows) compared to strong DFF40, Bcl-2, and moderate DFF45 expression 
in uterine leiomyomas (blue arrows).
Abbreviations: DFF40, Dna fragmentation factor 40; DFF45, Dna fragmentation factor 45; Bcl-2, B-cell lymphoma 2 protein.
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uLMS-M and uLM-M showed predominately low and mod-
erate DFF40 expression and scantly low and high expression 
(Table 2). No significant differences were observed in DFF40 
nor DFF45 scoring between uM, uLMS-M, and uLM-M 
(Table 2). Bcl-2 showed mainly moderate expression in uM 
and uLM-M, and low in uLMS-M (Table 2). No significant 
differences were observed in Bcl-2 expression between the 
uM, uLM-M, and uLMS-M groups.
In uM, a moderate positive and significant correlation 
between DFF40 and DFF45 expression was observed 
(R =0.762; p0.001), with no correlation between Bcl-2 and 
DFF40 or Bcl-2 and DFF45. In uLM-M, a strong positive and 
significant correlation between DFF40 and DFF45 was also 
proven (R =0.893; p0.001), with no association observed 
between Bcl-2 and DFF40 or Bcl-2 and DFF45. Additionally, 
in uLMS-M specimens, the only correlation observed was 
that between DFF40 and DFF45 (R =0.703; p0.001).
Validation of the intra-rater reliability for 
immunohistochemistry scoring
An excellent intra-rater agreement was confirmed with 
regard to the immunoscoring of DFF40, DFF45, and Bcl-2 
expression, and the following values were noted:
A) The first pathologist (ie, observer 1 vs 1) for the assessment 
of DFF40 showed, ICC 0.976 [confidence interval (CI) 
0.959–0.986]; for DFF45, ICC 0.934 (CI 0.900–0.961); 
and for Bcl-2, ICC 0.952 (CI 0.919–0.972).
B) The second pathologist (ie, observer 2 vs 2) for the assess-
ment of DFF40, ICC 0.934 (CI 0.889–0.961); for DFF45, 
ICC 0.898 (CI 0.831–0.929); and for Bcl-2, ICC 0.984 
(CI 0.972–0.990).
Discussion
To our knowledge, a comprehensive investigation of DFF40 
and DFF45 immunoexpression along with Bcl-2 staining in 
leiomyosarcomas and leiomyomas of the human uterus has 
not been reported previously. Many studies have confirmed 
Bcl-2 underexpression in uLMS and have identified it as 
a predictor of poor OS; in contrast, uLM shows increased 
expression of this protein.17,32,41–43 Our outcomes confirmed 
that the highest Bcl-2 expression was present in uLM, and 
the lowest in uLMS. Similarly, Bcl-2-negative uLMS cases 
presented with a significantly shorter DFS and OS. Addition-
ally, uLM specimens showed a lack of correlation between 
Bcl-2 and DFF40 or DFF45 expression.
As we found no studies concerning DFF40/DFF45 
expression in uLMS, our findings can only be discussed in 
the context of other malignancies. Both DFF40 and DFF45 T
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were underexpressed in uLMS, and DFF40-negative cases 
presented with significantly shorter DFS and OS; in contrast, 
DFF45 expression was not a predictive factor of OS or DFS. 
Sánchez-Osuna et al reported that DFF40-deficient high-
grade glioblastomas showed incomplete apoptosis, despite 
the correct activation of executioner caspases.44 Bagheri et al 
reported that DFF40 overexpression sensitized breast cancer 
cells to doxorubicin, concluding that modulation of DFF40 
levels may be a beneficial strategy for treatment of chemore-
sistant cancers.45 Additionally, Boon and Sim reported that 
the overexpression of only DFF40 in nasopharyngeal car-
cinomas did not result in increased apoptosis of head and 
neck squamous carcinoma in response to oxidative stress, as 
DFF45 was required for proper DFF40 folding.46
DFF45 deficiency was also reported as a cause of abnor-
mal cell apoptosis; this seems counterintuitive, as DFF45 is an 
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Figure 2 Disease-free survival (DFs) in women with leiomyosarcomas depending on DFF40 (A), DFF45 (B), and Bcl-2 (C) expression and disease stage (D) according to 
FIGO classification, tumor grade (E), and mitotic index (F); *p0.05 is statistically significant.
Abbreviations: DFF40, Dna fragmentation factor 40; DFF45, Dna fragmentation factor 45; Bcl-2, B-cell lymphoma 2 protein; FigO, international Federation of gynecology 
and Obstetrics.
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Figure 3 Overall survival (Os) in women with leiomyosarcomas depending on DFF40 (A), DFF45 (B), and Bcl-2 (C) expression, and disease stage (D) according to FigO 
classification, tumor grade (E), and mitotic index (F); *p0.05 is statistically significant.
Abbreviations: DFF40, Dna fragmentation factor 40; DFF45, Dna fragmentation factor 45; Bcl-2, B-cell lymphoma 2 protein; FigO, international Federation of gynecology 
and Obstetrics.
inhibitor of DFF40 and, thus, the lack of an inhibitor should 
result in increased activity of DNAse. However, it is important 
to note that DFF45 also acts as a chaperone for DFF40 and its 
presence is mandatory for proper DFF40 folding, which is, in 
turn, essential to the functional activation of DFF40. Errami 
et al proved that DFF45-negative colon cancer cells were 
more resistant to apoptosis than was normal colon tissue.35 
Furthermore, Konishi et al showed that esophageal squamous 
cancer cells exhibit abundant DFF45 expression, which cor-
related negatively with tumor grade and enhanced lymphatic 
spread.34 The only study to investigate DFF45 expression 
in gynecological malignancies, conducted by Brustmann, 
showed that DFF45 upregulation in serous ovarian cancer was 
correlated with aggressive tumor behavior.47 Another study 
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seems to be abrogated at earlier levels of the apoptotic 
cascade, before activation of DFF40/DFF45, and Bcl-2 
overexpression can enhance these mechanisms. Second, 
an exclusive increase in DFF40 expression, without a 
DFF45 increase, may be not sufficient for proper DFF40 
activation, as the presence of DFF45 is essential for DFF40 
to acquire its biological function. Unbalanced DFF40/
DF45 expression may be another mechanism allowing 
leiomyoma cells to escape apoptosis. In uLMS, significant 
decreases in DFF40 and DFF45 expression seem sufficient 
to prevent DNA laddering. Under these circumstances, 
functioning of factors involved in transmitting of pro- and 
anti-apoptotic signals (including low Bcl-2 expression) 
seems secondary.
In this study, we confirmed that DFF40, DFF45, and 
Bcl-2 underexpression in uLMS can enhance apoptosis 
dysregulation. Moreover, in malignant tissues, no correla-
tion was found between DFF40 and DFF45 expression. 
Dysregulation of DFF40 and DFF45 expression may be 
another mechanism underlying cell escape from apoptosis, 
as the presence of DFF45 is mandatory for proper DFF40 
function.
The main strength of the study is that it provides a com-
prehensive analysis of DFF40 and DFF45, simultaneously 
with Bcl-2 evaluation, in uLMS. We correlated DFF40 
and DFF45 expression with clinical malignancies and 
pathological features, showing that DFF40 and Bcl-2, but 
not DFF45, may serve as independent prognostic factors 
of DFS and OS. Moreover, protein expression in uLMS 
was not only compared with their expression in normal 
human myometrium, but also with cases of leiomyomas and 
myometrium from corresponding cases. In this analysis, no 
differences between case and control myometrium were seen 
in DFF40, DFF45, and Bcl-2 expression; these observations 
agree with the clonal theory of uLMS and uLM, which con-
firms the very low risk of malignant transformation of uLM. 
also showed increasing DFF45 immunoreactivity from nor-
mal endometrium through normal endometrial and atypical 
hyperplasia to endometrial adenocarcinomas.48 The results of 
DFF45 expression in different malignancies are inconclusive. 
In our study, we observed altered DFF45 staining in uLMS 
that correlated only with the stage of the disease, but did not 
influence DFS or OS.
Apoptosis is mainly triggered by either membrane death 
receptors or via the mitochondrial pathway, involving 
activation of many proapoptotic proteins and deactivation 
of anti-apoptotic factors.49,50 Furthermore, under persistent 
exposure to damaging agents, the endoplasmatic reticulum 
can initiate apoptosis through calcium release and activa-
tion of caspase 12.51 These mechanisms activate a cascade 
of caspases that exist mainly in the cytosol as pro-enzymes; 
a cross-talk between apoptotic factors then finally results in 
caspase-3 activation that cleaves DFF45, releasing DFF40, 
which is directly responsible for the last step of apoptosis: 
DNA laddering.24 Increased Bcl-2 expression in leiomyomas 
may explain an uncontrolled tumor proliferation, and con-
firms the monoclonal hypothesis of uterine fibroid formation.9 
In contrast to high Bcl-2 expression, we would rather have 
expected decreased DFF40 levels in uLM, as this protein 
results in the DNA damage. In uLMS, low levels of DFF40 
were intuitively predicted, although we expected higher 
levels of Bcl-2 as an anti-apoptotic protein. These apparently 
inconsistent and counterintuitive results are in agreement 
with other reports showing increased expression of some 
oncogenes in benign proliferative disorders and their deple-
tion in malignancies.27
Based on these findings, we hypothesize that benign 
tumors and malignancies may have developed different 
mechanisms to avoid apoptosis. In uLM, Bcl-2 overexpres-
sion seems important for preventing cells from undergoing 
apoptosis. High DFF40 levels make leiomyoma cells more 
susceptible to apoptosis; however, the proapoptotic signal 
Table 3 cox’s proportional hazard regression analysis of the prognostic value of clinical and immunohistochemical variables in 
53 women with uterine leiomyosarcomas
Prognostic factor Disease free survival (DFS) Overall survival (OS)
HR (CI) p-value HR (CI) p-value
age 0.973 (0.921–1.029) 0.348 0.964 (0.910–1.020) 0.206
stage 3+ 9.024 (1.196–81.968) 0.001# 14.153 (6.061–33.049) 0.001#
grade 3 2.226 (1.064–4.656) 0.031# 2.396 (1.148–4.999) 0.019#
Mi 50 4.674 (2.184–10.014) 0.001# 18.601 (5.703–60.670) 0.001#
negative DFF40 staining 3.254 (3.254–6.459) 0.007# 6.315 (2.712–14.704) 0.001#
negative DFF45 staining 1.359 (0.715–2.583) 0.349 1.587 (0.829–3.044) 0.164
negative Bcl-2 staining 3.893 (1.940–7.812) 0.001# 11.476 (4.454–29.564) 0.001#
Note: #p, significant p value.
Abbreviations: DFF40, DNA fragmentation factor 40; DFF45, DNA fragmentation factor 45; Bcl-2, B-cell lymphoma 2 protein; CI, confidence intervals; HR, hazard ratio; 
Mi, mitotic index.
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Finally, we observed a positive correlation between DFF40 
and DFF45 expression but not Bcl-2, in both control and 
case myometrial samples.
The use of immunohistochemistry, which is a semi-
quantitative method, may be considered a potential limitation 
of the study, especially for comparing DFF40 and DFF45 
expression in the same tissue. We acknowledge that an 
immunostaining analysis is subjective and, for that reason, 
each sample was evaluated by two highly experienced 
pathologists. This methodology is widely accepted and has 
been employed by many other studies for investigating the 
expression of DFF45 and Bcl-2.25–29,32 As complete inter-rater 
agreement was achieved, the intra-rater disparity was the only 
potential bias in our sample assessment. However, as this 
disparity showed an almost-perfect correlation, intra-rater 
bias can safely be excluded.
Conclusion
This current study provides important evidence regarding the 
underexpression of DFF40/DFF45 and Bcl-2 in uLMS, and 
shows that DFF40 and Bcl-2 may serve as prognostic factors 
for DFS and OS. This comprehensive evaluation provides 
more insight into other findings concerning DFF40, DFF45, 
and Bcl-2 expression in malignancies.
Acknowledgments
The authors thank Dr H Molak-Olczak, who independently 
and blindly analyzed the immunoexpression of the investi-
gated proteins as a second specialist in histopathology.
Author contributions
TB was the chief investigator who designed the study, 
selected the cases, conducted data analysis, and drafted 
the manuscript. KP and KO participated in the creation of 
the study design, specimen evaluation, and the selection of 
eligible cases. KO performed the protein immunoexpression 
assessment. AC performed statistical analysis and critically 
reviewed the manuscript. All authors contributed toward data 
analysis, drafting and critically revising the paper and agree 
to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 
116(1):131–139.
2. Zhiqiang L, Bin S, Min F, Yufang L. Leiomyosarcoma of cervical stump 
following subtotal hysterectomy: a case report and review of literature. 
Eur J Gynaecol Oncol. 2016;37(1):148–151.
 3. Khosla D, Gupta R, Srinivasan R, Patel FD, Rajwanshi A. Sarcomas 
of uterine cervix: clinicopathological features, treatment, and outcome. 
Int J Gynecol Cancer. 2012;22(6):1026–1030.
 4. Boll D, Verhoeven RH, van der Aa MA, et al. Incidence and survival 
trends of uncommon corpus uteri malignancies in the Netherlands, 
1989–2008. Int J Gynecol Cancer. 2012;22(4):599–606.
 5. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. 
Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12): 
1188–1198.
 6. Gottlieb S. Tamoxifen may increase risk for uterine sarcoma. Br Med J. 
2002;325:7.
 7. Naaman Y, Shveiky D, Ben-Shachar I, Shushan A, Mejia-Gomez J, 
Benshushan A. Uterine sarcoma: prognostic factor and treatment evalu-
ation. Isr Med Assoc J. 2011;13(2):76–79.
 8. NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms. 
Version 2. 2016. Accessed from: www.nccn.org. Accessed December 7, 
2016.
 9. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin 
Pathol. 1990;94(4):435–438.
10. Mittal K, Joutovsky A. Areas with benign morphologic and immunohis-
tochemical features are associated with some uterine leiomyosarcomas. 
Gynecol Oncol. 2007;104(2):362–365.
11. Mittal K. Precursor lesions for uterine leiomyosarcoma. Hum Pathol. 
2007;38(8):1289.
12. Zhang P, Zhang C, Hao J, et al. Use of X-chromosome inactivation 
pattern to determine the clonal origins of uterine leiomyoma and leio-
myosarcoma. Hum Pathol. 2006;37(10):1350–1356.
13. Gadducci A, Sartori E, Landoni F, et al. The prognostic relevance 
of histological type in uterine sarcomas: a Cooperation Task Force 
(CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol. 2002; 
23(4):295–289.
14. Raspollini MR, Amunni G, Villanucci A, et al. Estrogen and progester-
one receptors expression in uterine malignant smooth muscle tumors: 
correlation with clinical outcome. J Chemother. 2003;15(6):596–602.
15. Smirnova IS, Yakovleva TK, Rosanov YM, Aksenov ND, Pospelova TV. 
Analysis of p53-dependent mechanisms in the maintenance of genetic 
stability in diploid tumourigenic line SK-UT-1B of human uterine 
leiomyosarcoma. Cell Biol Int. 2001;25(11):1101–1115.
16. Kułak K, Bobiński M, Polak G, Jedrych BJ, Kotarski J, Bednarek W. 
Ocena ekspresji kaspazy 9 i bialka p53 w miesakach macicy. [Expres-
sion of caspase 9 and p53 in uterine leiomyosarcomas]. Ginekol Pol. 
2014;85(8):600–604. Polish
17. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Mayerhofer K. 
Bcl-2 expression and other clinicopathologic parameters in uterine 
leiomyosarcoma. Wien Klin Wochenschr. 2004;116(4):135–139.
18. Kowalewska M, Bakula-Zalewska E, Chechlinska M, et al. microRNAs 
in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: 
a preliminary report. Tumour Biol. 2013;34(4):2153–2160.
19. Barlin JN, Zhou QC, Leitao MM, et al. Molecular subtypes of uterine 
leiomyosarcoma and correlation with clinical outcome. Neoplasia. 
2015;17(2):183–189.
20. Cekanova M, Fernando RI, Siriwardhana N, et al. BCL-2 family protein, 
BAD is down-regulated in breast cancer and inhibits cell invasion. 
Exp Cell Res. 2015;331(1):1–10.
21. Chaudhry P, Srinivasan R, Patel FD. Differential expression of Fas 
family members and Bcl-2 family members in benign versus malignant 
epithelial ovarian cancer (EOC) in North Indian population. Mol Cell 
Biochem. 2012;368(1–2):119–126.
22. Dorjgochoo T, Xiang YB, Long J, et al. Association of genetic markers 
in the BCL-2 family of apoptosis-related genes with endometrial cancer 
risk in a Chinese population. PLoS One. 2013;8(4):e60915.
23. Mao PL, Jiang Y, Wee BY, Porter AG. Activation of caspase-1 in the 
nucleus requires nuclear translocation of pro-caspase-1 mediated by its 
prodomain. J Biol Chem. 1998;273(37):23621–23624.
24. Fukushima K, Kikuchi J, Koshiba S, Kigawa T, Kuroda Y, Yokoyama S. 
Solution structure of the DFF-C domain of DFF45/ICAD. A structural 
basis for the regulation of apoptotic DNA fragmentation. J Mol Biol. 
2002;321(2):317–327.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open 
access journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
4589
Predictive value of DFF40/DFF45 and Bcl-2 in uterine leiomyoscarcomas
25. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family 
and related proteins in mammary gland involution and breast cancer. 
J Mammary Gland Biol Neoplasia. 1999;4(2):153–164.
26. Khodapasand E, Jafarzadeh N, Farrokhi F, Kamalidehghan B, 
Houshmand M. Is Bax/Bcl-2 ratio considered as a prognostic marker 
with age and tumor location in colorectal cancer? Iran Biomed J. 2015; 
19(2):69–75.
27. Nakamura T, Nomura S, Sakai T, Nariya S. Expression of bcl-2 oncopro-
tein in gastrointestinal and uterine carcsinomas and their premalignant 
lesions. Hum Pathol. 1997;28(3):309–315.
28. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. 
Lack of bcl-2 persistence: an independent prognostic indicator of poor 
prognosis in endometrial carcinoma. Gynecol Oncol. 1998;71(2): 
305–307.
29. Hwang KT, Han W, Kim J, et al. Prognostic influence of BCL2 on molec-
ular subtypes of breast cancer. J Breast Cancer. 2017;20(1):54–64.
30. Porichi O, Nikolaidou ME, Apostolaki A, et al. BCL-2, BAX and 
P53 expression profiles in endometrial carcinoma as studied by real-
time PCR and immunohistochemistry. Anticancer Res. 2009;29(10): 
3977–3982.
31. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. 
Lack of bcl-2 persistence: an independent prognostic indicator of poor 
prognosis in endometrial carcinoma. Gynecol Oncol. 1998;71(2): 
305–307.
32. Zhai YL, Nikaido T, Toki T, Shiozawa A, Orii A, Fujii S. Prognostic 
significance of bcl-2 expression in leiomyosarcoma of the uterus. 
Br J Cancer. 1999;80(10):1658–1664.
33. Rajandram R, Razack AH, Ng KL, Gobe GC. Decreased expres-
sion of inhibitor of caspase-activated DNase (ICAD) in renal cell 
carcinoma – tissue microarray of human samples. J Kidney Cancer VHL. 
2016;3(1):1–11.
34. Konishi S, Ishiguro H, Shibata Y, et al. Decreased expression of DFF45/
ICAD is correlated with a poor prognosis in patients with esophageal 
carcinoma. Cancer. 2002;95(12):2473–2478.
35. Errami Y, Brim H, Oumouna-Benachour K, et al. ICAD deficiency in 
human colon cancer and predisposition to colon tumorigenesis: linkage 
to apoptosis resistance and genomic instability. PLoS One. 2013; 
8(2):e57871.
36. Banas T, Basta P, Knafel A, et al. DFF45 expression in human endo-
metrium is associated with menstrual cycle phases and decreases after 
menopause. Gynecol Obstet Invest. 2012;73:177–182.
37. Banas T, Skotniczny K, Basta A. DFF45 expression in ovarian endo-
metriomas. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):87–91.
38. Remmele W, Stegner HE. Recommendation for uniform definition of an 
immunoreactive score (IRS) for immunohistochemical estrogen recep-
tor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8(3): 
138–140. [Article in German]
39. Preacher KJ. Calculation for the chi-square test: an interactive calcu-
lation tool for chi-square tests of goodness of fit and independence 
[Computer software]. Available from: http://quantpsy.org. Accessed 
January 2, 2017.
40. Kottner J, Audige L, Brorson S, et al. Guidelines for reporting reliability 
and agreement studies (GRRAS) were proposed. Int J Nurs Stud. 2011; 
48(6):661–671.
41. Kobayashi H, Uekuri C, Akasaka J, et al. The biology of uterine 
sarcomas: a review and update. Mol Clin Oncol. 2013;1(4):599–609.
42. Leiser AL, Anderson SE, Nonaka D, et al. Apoptotic and cell cycle 
regulatory markers in uterine leiomyosarcoma. Gynecol Oncol. 2006; 
101(1):86–91.
43. D’Angelo E, Espinosa I, Ali R, et al. Uterine leiomyosarcomas: tumor 
size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups 
with different prognosis. Gynecol Oncol. 2011;121(2):328–333.
44. Sánchez-Osuna M, Martínez-Escardó L, Granados-Colomina C, et al. 
An intrinsic DFF40/CAD endonuclease deficiency impairs oligo-
nucleosomal DNA hydrolysis during caspase-dependent cell death: 
a common trait in human glioblastoma cells. Neuro Oncol. 2016;18(7): 
950–961.
45. Bagheri F, Safarian S, Eslaminejad MB, Sheibani N. Sensitization of 
breast cancer cells to doxorubicin via stable cell line generation and 
overexpression of DFF40. Biochem Cell Biol. 2015;93(6):604–610.
46. Boon SS, Sim SP. Inhibitor of caspase-activated DNase expression 
enhances caspase-activated DNase expression and inhibits oxidative 
stress-induced chromosome breaks at the mixed lineage leukaemia gene 
in nasopharyngeal carcinoma cells. Cancer Cell Int. 2015;15:54.
47. Brustmann H. DNA fragmentation factor (DFF45): expression and 
prognostic value in serous ovarian cancer. Pathol Res Pract. 2006; 
202(10):713–720.
48. Brustmann H. Poly(ADP-ribose) polymerase (PARP) and DNA-
fragmentation factor (DFF45): expression and correlation in normal, 
hyperplastic and neoplastic endometrial tissues. Pathol Res Pract. 2007; 
203(2):65–72.
49. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355–356.
50. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alterna-
tive mechanisms. Nat Rev Mol Cell Biol. 2001;2(8):589–598.
51. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of 
calcium signaling. Nat Rev Mol Cell Biol. 2000;1(1):11–21.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
